Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study

Abstract Background Tunlametinib (HL-085) is a novel, highly selective MEK inhibitor with substantial clinical activities in patients with NRAS-mutant melanoma. This phase I study evaluated the safety and preliminary efficacy of tunlametinib plus vemurafenib in patients with advanced BRAF V600-mutan...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yuankai Shi, Xiaohong Han, Qian Zhao, YuLong Zheng, Jianhua Chen, Xinmin Yu, Jian Fang, Yutao Liu, Dingzhi Huang, Tianshu Liu, Hong Shen, Suxia Luo, Hongsheng Yu, Yu Cao, Xi Zhang, Pei Hu
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-06-01
Col·lecció:	Experimental Hematology & Oncology
Matèries:	Tunlametinib MEK inhibitor Vemurafenib BRAF Non-small cell lung cancer Colorectal cancer
Accés en línia:	https://doi.org/10.1186/s40164-024-00528-0
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!